表紙
市場調査レポート

子宮内膜症:パイプライン製品の分析

Endometriosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232822
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
子宮内膜症:パイプライン製品の分析 Endometriosis - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 131 Pages
概要

子宮内膜症とは、通常は子宮内部にある組織(子宮内膜)が子宮の外部にまで拡大する(子宮内膜移植)という疾患で、しばしば痛みを伴います。主な症状として、骨盤痛や月経痙攣、炎症、不妊症、異常出血などが挙げられます。疾病素質には、排尿の不順や、骨盤内感染症の病歴、家族歴などが含まれています。主な治療薬には、非ステロイド系抗炎症性薬物(NSAID)や経口避妊薬、黄体ホルモン物質などがあります。

当レポートでは、世界各国での子宮内膜症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

子宮内膜症の概要

治療薬の開発

  • 子宮内膜症向けパイプライン製品:概要
  • 子宮内膜症向けパイプライン製品:比較分析

各企業で開発中の子宮内膜症治療薬

大学/研究機関で研究中の子宮内膜症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

子宮内膜症治療薬:開発中の製品の一覧(企業別)

子宮内膜症治療薬:研究中の製品の一覧(大学/研究機関別)

子宮内膜症治療薬の開発に従事している企業

  • Euroscreen S.A.
  • 武田薬品工業
  • Neurocrine Biosciences, Inc.
  • アステラス製薬
  • キッセイ薬品
  • SK Chemicals Co., Ltd.
  • Bayer AG
  • Addex Therapeutics
  • Evotec AG
  • ValiRx Plc
  • Repros Therapeutics Inc.
  • Dongkook Pharmaceutical Co., Ltd.
  • Camurus AB
  • Lipicard Technologies Limited
  • Orphagen Pharmaceuticals, Inc.
  • Peptron, Inc.
  • PregLem SA
  • EndoCeutics, Inc.
  • Isifer AB
  • ElexoPharm GmbH
  • APAvadis Biotechnologies Srl
  • AbbVie Inc.
  • Balonco GMBH
  • Forendo Pharma Oy

子宮内膜症:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • elagolix sodium
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • 酢酸ロイプロリドSR(持続放出)
  • degarelix
  • acolbifene+DHEA+GnRH作動薬
  • relugolix
  • 酢酸テラプリストン
  • PGL-2001
  • KLH-2109
  • ASP-1707
  • Endole
  • ベンタマピモド
  • テベレリックス
  • BAY-1026153
  • ADX-68692
  • ESN-364
  • VAL-201
  • 酢酸ロイプロリド
  • GnRH拮抗薬
  • 子宮内膜症・乳がん向け17 Beta-HSD1阻害用小分子
  • HSD研究プログラム
  • 子宮内膜症向け小分子
  • NCE-403
  • アミノペプチダーゼA計画
  • METAプログラム
  • 皮膚病・ホルモン障害・非悪性疾患・腫瘍・婦人病むけGnRH受容体阻害薬
  • EVE-104
  • EC-304
  • トリプトレリンパモ酸塩のバイオシミラー
  • ゴセレリンのバイオシミラー
  • LT-6121
  • キスペプチン・ペプチド拮抗薬
  • 子宮内膜症向け17HSD1阻害用小分子
  • 遺伝子組み換え型色素上皮由来因子
  • VPE-001
  • 子宮内膜症・エストロゲン依存性がん向け17βヒドロキシステロイドデヒドロゲナーゼ1型阻害用小分子
  • 子宮内膜症向けRERG標的医薬品
  • 子宮内膜症向けプロスタノイドEP2・EP4受容体阻害用小分子
  • ステロイド産生因子-1拮抗薬
  • 婦人病向けプログラム
  • EMMPRIN抱合体
  • Axl/Gas6シグナリング阻害薬
  • 子宮内膜症向けC-Jun阻害薬

子宮内膜症治療薬:パイプライン製品の最新動向

子宮内膜症治療薬:開発が休止状態の製品

子宮内膜症治療薬:開発が中止された製品

子宮内膜症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7713IDB

Summary

Global Markets Direct's, 'Endometriosis - Pipeline Review, H1 2016', provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endometriosis
  • The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects
  • The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Endometriosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endometriosis Overview
  • Therapeutics Development
    • Pipeline Products for Endometriosis - Overview
    • Pipeline Products for Endometriosis - Comparative Analysis
  • Endometriosis - Therapeutics under Development by Companies
  • Endometriosis - Therapeutics under Investigation by Universities/Institutes
  • Endometriosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Endometriosis - Products under Development by Companies
  • Endometriosis - Products under Investigation by Universities/Institutes
  • Endometriosis - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • APAvadis Biotechnologies Srl
    • Astellas Pharma Inc.
    • Bayer AG
    • Dongkook Pharmaceutical Co., Ltd.
    • ElexoPharm GmbH
    • EndoCeutics, Inc.
    • Euroscreen S.A.
    • Evotec AG
    • Forendo Pharma Limited
    • GlaxoSmithKline Plc
    • Kissei Pharmaceutical Co., Ltd.
    • Lipicard Technologies Limited
    • Nippon Shinyaku Co., Ltd.
    • Orphagen Pharmaceuticals, Inc.
    • Philogen S.p.A.
    • Repros Therapeutics Inc.
    • SK Chemicals Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • ValiRx Plc
  • Endometriosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (anastrozole + levonorgestrel) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-1707 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1128688 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bentamapimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit C-Jun for Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elagolix sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epelsiban besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVE-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-5677 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • goserelin biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KLH-2109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-6121 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIA-602 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-580 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides for Hepatic Tumor and Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Inhibit Aminopeptidase A for Hepatic (Liver) Tumor and Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGL-2001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relugolix - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKI-2670 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SR-16234 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • telapristone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tetravil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triptorelin biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vilaprisan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VPEA-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Endometriosis - Recent Pipeline Updates
  • Endometriosis - Dormant Projects
  • Endometriosis - Discontinued Products
  • Endometriosis - Product Development Milestones
    • Featured News & Press Releases
      • Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
      • Dec 21, 2015: Repros Updates Proellex Program
      • Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on BAY 98-7196 at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
      • Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
      • Feb 26, 2015: New Endometriosis Patent Grant for ValiRx
      • Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications
      • Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis
      • Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
      • Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201
      • Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Endometriosis, H1 2016
  • Number of Products under Development for Endometriosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Endometriosis - Pipeline by AbbVie Inc., H1 2016
  • Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2016
  • Endometriosis - Pipeline by Astellas Pharma Inc., H1 2016
  • Endometriosis - Pipeline by Bayer AG, H1 2016
  • Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016
  • Endometriosis - Pipeline by ElexoPharm GmbH, H1 2016
  • Endometriosis - Pipeline by EndoCeutics, Inc., H1 2016
  • Endometriosis - Pipeline by Euroscreen S.A., H1 2016
  • Endometriosis - Pipeline by Evotec AG, H1 2016
  • Endometriosis - Pipeline by Forendo Pharma Limited, H1 2016
  • Endometriosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Endometriosis - Pipeline by Lipicard Technologies Limited, H1 2016
  • Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016
  • Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016
  • Endometriosis - Pipeline by Philogen S.p.A., H1 2016
  • Endometriosis - Pipeline by Repros Therapeutics Inc., H1 2016
  • Endometriosis - Pipeline by SK Chemicals Co., Ltd., H1 2016
  • Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Endometriosis - Pipeline by ValiRx Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Endometriosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Endometriosis - Dormant Projects, H1 2016
  • Endometriosis - Dormant Projects (Contd..1), H1 2016
  • Endometriosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Endometriosis, H1 2016
  • Number of Products under Development for Endometriosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top